Copiktra 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
PSUSA/10939
Periodic Safety Update EU Single assessment - 
07/04/2022 
n/a 
PRAC Recommendation - maintenance 
/202109 
duvelisib 
II/0002 
Update of section 5.1 of the SmPC based on the final 
27/01/2022 
SmPC 
For more information, please refer to the Summary of 
overall survival results from Study IPI-145-07, an 
interventinal Phase 3 Study of duvelisib (IPI-145) vs 
Product Characteristics. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
ofatumumab in patients with relapsed or refractory 
Chronic Lymphocytic leukemia/Small Lymphocytic 
Lymphoma. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
T/0001 
Transfer of Marketing Authorisation 
16/07/2021 
20/08/2021 
SmPC, 
Labelling and 
PL 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
